Avalo Therapeutics' (AVTX) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• Weiss Ratings has reiterated a "sell (D-)" rating for Avalo Therapeutics (AVTX), despite mixed ratings from other analysts.
• Avalo Therapeutics recently reported a quarterly loss of ($1.92) EPS, missing estimates, and is projected to have a fiscal year EPS of (-19.07).
• The stock is currently priced at $13.88, with a moderate buy consensus from nine analysts and an average price target of $31.67.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report)'s stock had its "sell (d-)" rating restated by equities researchers at Weiss Ratings in a research note issued on Tuesday,Weiss Ratings reports.

Other analysts have also issued reports about the company. Cantor Fitzgerald began coverage on Avalo Therapeutics in a report on Friday, August 15th. They issued an "overweight" rating on the stock. BTIG Research reissued a "buy" rating and set a $40.00 price objective on shares of Avalo Therapeutics in a research note on Monday, September 29th. Cowen assumed coverage on shares of Avalo Therapeutics in a report on Friday, September 5th. They issued a "buy" rating on the stock. HC Wainwright upped their price objective on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a report on Wednesday, September 17th. Finally, TD Cowen started coverage on shares of Avalo Therapeutics in a research report on Friday, September 5th. They set a "buy" rating on the stock. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Avalo Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $31.67.

Avalo Therapeutics Stock Performance

Avalo Therapeutics stock traded up $0.21 during trading hours on Tuesday, reaching $13.88. The stock had a trading volume of 66,234 shares, compared to its average volume of 159,489. The business's 50 day moving average price is $10.80 and its 200-day moving average price is $7.06. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $16.00.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.43) by ($0.49). Research analysts expect that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Institutional Trading of Avalo Therapeutics

Large investors have recently made changes to their positions in the stock. Quadrature Capital Ltd acquired a new stake in shares of Avalo Therapeutics during the second quarter worth $55,000. Boothbay Fund Management LLC acquired a new position in Avalo Therapeutics during the 2nd quarter worth approximately $56,000. ADAR1 Capital Management LLC acquired a new position in shares of Avalo Therapeutics during the first quarter worth $80,000. Geode Capital Management LLC lifted its stake in shares of Avalo Therapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company's stock worth $552,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Velan Capital Investment Management LP raised its stake in shares of Avalo Therapeutics by 38.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 154,972 shares of the company's stock valued at $773,000 after purchasing an additional 43,000 shares in the last quarter. Institutional investors and hedge funds own 87.06% of the company's stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.